Dr. Corrado Lodigiani has been assistant at the Thrombosis Centre of Humanitas research Hospital from 1998 to 2013 and he became Unit Director in 2013.
Humanitas Thrombosis Center is a state-of-the-art service for the proper management of the diagnosis and therapy of venous thromboembolic pathology (deep and superficial venous thrombosis, pulmonary thromboembolism, visceral venous thrombosis) and arterial (myocardial infarction, cerebral stroke, peripheral arterial disease).
Other also rare diseases treated are atypical thrombosis, such as the vascular circulation of the retina, the hearing system and the placental circulation during pregnancy.
Dr. Lodigiani adopts the multidisciplinary approach and works in collaboration with all medical and surgical specialties. In particular, he carries out clinical and instrumental diagnostics (vascular ecocolordoppler) and research on the causes, diagnosis and therapy of thrombotic and bleeding disorders, congenital and acquired. His clinical activity also involves the diagnosis and management of patients suffering from bleeding diseases, such as haemophilia, von Willebrand’s disease and platelet diseases.
In recent years, he has devoted himself with particular interest to the testing, in the role of Principal Investigator in International Clinical Studies, of new antithrombotic drugs and, above all, anticoagulants, which are about to be marketed and will constitute a valid and safe alternative to traditional oral anticoagulant therapy (DOACs). He is also working, with great interest, on researching the causes of idiopathic infertility and the usefulness and effectiveness of some therapeutic strategies, such as the use of anticoagulant drugs, improving the results of artificial insemination procedures. He is the author of numerous articles in international scientific journals and speaker at numerous national and international conferences.
Mostrar másDr. Corrado Lodigiani has been assistant at the Thrombosis Centre of Humanitas research Hospital from 1998 to 2013 and he became Unit Director in 2013.
Humanitas Thrombosis Center is a state-of-the-art service for the proper management of the diagnosis and therapy of venous thromboembolic pathology (deep and superficial venous thrombosis, pulmonary thromboembolism, visceral venous thrombosis) and arterial (myocardial infarction, cerebral stroke, peripheral arterial disease).
Other also rare diseases treated are atypical thrombosis, such as the vascular circulation of the retina, the hearing system and the placental circulation during pregnancy.
Dr. Lodigiani adopts the multidisciplinary approach and works in collaboration with all medical and surgical specialties. In particular, he carries out clinical and instrumental diagnostics (vascular ecocolordoppler) and research on the causes, diagnosis and therapy of thrombotic and bleeding disorders, congenital and acquired. His clinical activity also involves the diagnosis and management of patients suffering from bleeding diseases, such as haemophilia, von Willebrand’s disease and platelet diseases.
In recent years, he has devoted himself with particular interest to the testing, in the role of Principal Investigator in International Clinical Studies, of new antithrombotic drugs and, above all, anticoagulants, which are about to be marketed and will constitute a valid and safe alternative to traditional oral anticoagulant therapy (DOACs). He is also working, with great interest, on researching the causes of idiopathic infertility and the usefulness and effectiveness of some therapeutic strategies, such as the use of anticoagulant drugs, improving the results of artificial insemination procedures. He is the author of numerous articles in international scientific journals and speaker at numerous national and international conferences.
Prof. Alberto Albanese is the Neurology Unit Director at Humanitas Research Hospital. Until recently – Department Head of Neuroscience at the Institute of Neurology Carlo Besta (Milan). In 1977 prof. Albanese received his degree in medicine and surgery, in 1981 – in neurology, and in 1985 – in psychiatry. His professional experience began with the founding of the Department of “disorders of Parkinson’s and violations of the musculoskeletal system” at the clinic “A. Gemelli “in Rome in 1984, which he led until 1996. From 1996 to 2000 prof. Albanese was the Head of the Neurological University Clinic of Lausanne (Switzerland) and a professor of Neurology in the University.
From 2000 to 2015 he was Head of Neuroscience Department at the Institute of Neurology Carlo Besta (Milan).
Prof. Albanese is a professor of neurology at the Institute of Neurology at the Catholic University of the Sacred Heart (Milan), Director of the post-graduate course “Diagnosis and treatment of movement disorders and degenerative neurological diseases” at the Foundation Neurological Institute “C. Besta”, as well as an adjunct professor at the School of Specialization in Neuroscience at the University of Milan Bicocca.
Prof. Albanese is the president of “Italian Association of Parkinson’s disease and movement disorders” and “Italian Association for the Study of the autonomic nervous system” (which are part of “Italian Community of Neuroscience”). He is also an honorary member of the “French Community of Neuroscience.” The professor is a moderator and speaker at major national and international neurological conferences, he organized several symposia dedicated to Neurology, collaborates with numerous national and international research centers, which are studying Parkinson’s disease, movement disorders and degenerative neurological diseases. Prof. Albanese has been repeatedly receiving research fundings from the following government agencies: the Ministry of Health, Ministry of Science and Research, National Research Council, the British Council, the Swiss National Research Council.
He is one of the greatest Italian experts on the diagnosis and treatment of neurological diseases and movement disorders, Parkinson.
He has extensive experience in the use of neurostimulation of brain neurological movement disorders, for treating Parkinson’s disease and other involuntary movements.
He developed the first Italian project on the study of genetic disease and Parkinson’s dystonia, which led to the discovery of two new genetic loci. Also prof. Albanese is actively engaged in research in the field of semiotics detailed definition of involuntary movements, which allows tracking of related clinical pathology for accurate diagnosis of patients with movement disorders.
Prof. Albanese has published more than 200 scientific papers, most of which are published in indexed journals (with a total impact factor>500), is the author of one monograph, 3 books and co-author of numerous books and publications. He is the chief editor of “Frontiers in Movement Disorders” and assistant editor of the “European Journal of Neuroscience”.
Publications: http://www.ncbi.nlm.nih.gov/pubmed?term=albanese a
Mostrar másProf. Alberto Albanese is the Neurology Unit Director at Humanitas Research Hospital. Until recently – Department Head of Neuroscience at the Institute of Neurology Carlo Besta (Milan). In 1977 prof. Albanese received his degree in medicine and surgery, in 1981 – in neurology, and in 1985 – in psychiatry. His professional experience began with the founding of the Department of “disorders of Parkinson’s and violations of the musculoskeletal system” at the clinic “A. Gemelli “in Rome in 1984, which he led until 1996. From 1996 to 2000 prof. Albanese was the Head of the Neurological University Clinic of Lausanne (Switzerland) and a professor of Neurology in the University.
From 2000 to 2015 he was Head of Neuroscience Department at the Institute of Neurology Carlo Besta (Milan).
Prof. Albanese is a professor of neurology at the Institute of Neurology at the Catholic University of the Sacred Heart (Milan), Director of the post-graduate course “Diagnosis and treatment of movement disorders and degenerative neurological diseases” at the Foundation Neurological Institute “C. Besta”, as well as an adjunct professor at the School of Specialization in Neuroscience at the University of Milan Bicocca.
Prof. Albanese is the president of “Italian Association of Parkinson’s disease and movement disorders” and “Italian Association for the Study of the autonomic nervous system” (which are part of “Italian Community of Neuroscience”). He is also an honorary member of the “French Community of Neuroscience.” The professor is a moderator and speaker at major national and international neurological conferences, he organized several symposia dedicated to Neurology, collaborates with numerous national and international research centers, which are studying Parkinson’s disease, movement disorders and degenerative neurological diseases. Prof. Albanese has been repeatedly receiving research fundings from the following government agencies: the Ministry of Health, Ministry of Science and Research, National Research Council, the British Council, the Swiss National Research Council.
He is one of the greatest Italian experts on the diagnosis and treatment of neurological diseases and movement disorders, Parkinson.
He has extensive experience in the use of neurostimulation of brain neurological movement disorders, for treating Parkinson’s disease and other involuntary movements.
He developed the first Italian project on the study of genetic disease and Parkinson’s dystonia, which led to the discovery of two new genetic loci. Also prof. Albanese is actively engaged in research in the field of semiotics detailed definition of involuntary movements, which allows tracking of related clinical pathology for accurate diagnosis of patients with movement disorders.
Prof. Albanese has published more than 200 scientific papers, most of which are published in indexed journals (with a total impact factor>500), is the author of one monograph, 3 books and co-author of numerous books and publications. He is the chief editor of “Frontiers in Movement Disorders” and assistant editor of the “European Journal of Neuroscience”.
Publications: http://www.ncbi.nlm.nih.gov/pubmed?term=albanese a
Dr. Mehdi Afrit is a Medical Oncologist who practices at Burjeel Specialty Hospital in Sharjah. He has over 11 years of experience caring for and managing cancer patients. He has extensive experience providing chemotherapy, hormonal therapy, immunotherapy, and targeted therapy to patients. He earned a Certificate of Medical Oncology from the Gustave Roussy Institute in Paris, France, where he received training in antitumor chemotherapy and cancer medical treatment. Additionally, he holds an international certificate in breast diseases. He also has a certificate in Good Clinical Practice from Trans Celerate Biopharma Inc. and a certificate in Clinical Trial Management: Good Clinical Practice from the Faculty of Pharmaceutical Medicine of the Royal College of Physicians. He previously worked for over five years as an Assistant Professor of Medical Oncology at Tunis’s Faculty of Medicine. He later practiced as a Consultant, Medical Oncologist for six years at Arianna’s hospital in Tunisia. He later worked for two years as a Specialist Medical Oncologist at Zulekha Hospital. He was also an investigator in three international clinical trials and holds clinical trial auditing and CRO certifications and a GCP Training Certificate from 2016. He is a member in good standing of the Emirates Oncology Society (EOS), the European Society of Medical Oncology (ESMO), and the American Society of Clinical Oncology (ASCO). His clinical expertise includes but is not limited to the following:
Dr. Mehdi Afrit is a Medical Oncologist who practices at Burjeel Specialty Hospital in Sharjah. He has over 11 years of experience caring for and managing cancer patients. He has extensive experience providing chemotherapy, hormonal therapy, immunotherapy, and targeted therapy to patients. He earned a Certificate of Medical Oncology from the Gustave Roussy Institute in Paris, France, where he received training in antitumor chemotherapy and cancer medical treatment. Additionally, he holds an international certificate in breast diseases. He also has a certificate in Good Clinical Practice from Trans Celerate Biopharma Inc. and a certificate in Clinical Trial Management: Good Clinical Practice from the Faculty of Pharmaceutical Medicine of the Royal College of Physicians. He previously worked for over five years as an Assistant Professor of Medical Oncology at Tunis’s Faculty of Medicine. He later practiced as a Consultant, Medical Oncologist for six years at Arianna’s hospital in Tunisia. He later worked for two years as a Specialist Medical Oncologist at Zulekha Hospital. He was also an investigator in three international clinical trials and holds clinical trial auditing and CRO certifications and a GCP Training Certificate from 2016. He is a member in good standing of the Emirates Oncology Society (EOS), the European Society of Medical Oncology (ESMO), and the American Society of Clinical Oncology (ASCO). His clinical expertise includes but is not limited to the following:
Since 1998 he has been Director of the Epilepsy Unit at the Ruber International Hospital in Madrid, a pioneering centre for the diagnosis, medical and surgical treatment of epilepsy in children and adults.
More than 150 neurologists and neurophysiologists from Spain and Latin America have been trained here, and several of its students have successfully opened epilepsy centres in other public and private hospitals, both in Spain and abroad.
The program he directs has become a pioneer in Spain in the field of genetic diagnosis of complex epilepsies and advanced treatments such as drug repositioning, interstitial laser treatment, deep electrodes and gamma radiosurgery, which are used in patients with refractory epilepsy.
Dr. Antonio Gil-Nagel is a professor at the IE University, is an Ad Honorem Professor at the Center for Biomedical Technology of the Polytechnic University of Madrid (CTB) and is Director of the Epilepsy Department at the Francisco Vitoria University of Madrid.
He was a founding member of the European Epilepsy Research Network and the European Association for Epilepsy Monitoring. He is also active in international research projects such as EpiCare and the European Epilepsy Brain Bank and has held relevant positions in international institutions such as the International Bureau for Epilepsy (IBE), the International League Against Epilepsy (ILAE), the European Federation of Neurological Societies (EFNS) and the World Federation of Neurology (WFN).
Dr. Gil-Nagel has directed numerous clinical trials and research studies in the field of epilepsy, especially in orphan epilepsies such as Dravet syndrome, Lennox-Gastaut syndrome and other epileptic and developmental encephalopathies. The Epilepsy Program he directs is an international benchmark in the development of pharmacological research. He has been the Principal Investigator of phase II and III clinical trials, including numerous clinical trials and non-pharmacological treatments (epilepsy surgery, electrical stimulation, ketogenic diet and gamma knife). His research is funded by European Union funds and the Public Innovation Agency of the Ministry of Science and Innovation of the Spanish Government. Their dedication to research and the development of new treatments allows them to accelerate the treatment of their patients with new treatments.
In addition to being a frequent speaker at national and international conferences, he has authored several books on epilepsy and electroencephalography and has numerous publications on epilepsy in journals such as Annals of Neurology, Brain, Epilepsy, European Journal of Neurology, Journal of Neurology, Nature Neurology, Neurology, and the New England Journal of Medicine, among others. He has authored 165 Scopus-indexed articles with 5,265 citations and an h-index of 35.
In 2021, his team received the Innovative Small and Medium Enterprise Award for the project on mesial temporal lobe epilepsy and encephalocele (Ministry of Science and Innovation, Spain), and in 2012, the Scientific Award from the Epilepsy Group of the Spanish Society of Neurology (SEN).
Dr. Hill-Nagel is a leading international figure in the field of epileptology, a recognized expert in the diagnosis and treatment of genetic epilepsy and the surgical approach to its correction. His distinguished professional career includes many years of experience in leading medical institutions in the United States and Europe, as well as active participation in international research and educational programs.
Dr. Hill-Nagel not only advances the science of neurology on a global level, but also successfully implements cutting-edge treatment methods, improving the lives of thousands of patients around the world.
Mostrar másSince 1998 he has been Director of the Epilepsy Unit at the Ruber International Hospital in Madrid, a pioneering centre for the diagnosis, medical and surgical treatment of epilepsy in children and adults.
More than 150 neurologists and neurophysiologists from Spain and Latin America have been trained here, and several of its students have successfully opened epilepsy centres in other public and private hospitals, both in Spain and abroad.
The program he directs has become a pioneer in Spain in the field of genetic diagnosis of complex epilepsies and advanced treatments such as drug repositioning, interstitial laser treatment, deep electrodes and gamma radiosurgery, which are used in patients with refractory epilepsy.
Dr. Antonio Gil-Nagel is a professor at the IE University, is an Ad Honorem Professor at the Center for Biomedical Technology of the Polytechnic University of Madrid (CTB) and is Director of the Epilepsy Department at the Francisco Vitoria University of Madrid.
He was a founding member of the European Epilepsy Research Network and the European Association for Epilepsy Monitoring. He is also active in international research projects such as EpiCare and the European Epilepsy Brain Bank and has held relevant positions in international institutions such as the International Bureau for Epilepsy (IBE), the International League Against Epilepsy (ILAE), the European Federation of Neurological Societies (EFNS) and the World Federation of Neurology (WFN).
Dr. Gil-Nagel has directed numerous clinical trials and research studies in the field of epilepsy, especially in orphan epilepsies such as Dravet syndrome, Lennox-Gastaut syndrome and other epileptic and developmental encephalopathies. The Epilepsy Program he directs is an international benchmark in the development of pharmacological research. He has been the Principal Investigator of phase II and III clinical trials, including numerous clinical trials and non-pharmacological treatments (epilepsy surgery, electrical stimulation, ketogenic diet and gamma knife). His research is funded by European Union funds and the Public Innovation Agency of the Ministry of Science and Innovation of the Spanish Government. Their dedication to research and the development of new treatments allows them to accelerate the treatment of their patients with new treatments.
In addition to being a frequent speaker at national and international conferences, he has authored several books on epilepsy and electroencephalography and has numerous publications on epilepsy in journals such as Annals of Neurology, Brain, Epilepsy, European Journal of Neurology, Journal of Neurology, Nature Neurology, Neurology, and the New England Journal of Medicine, among others. He has authored 165 Scopus-indexed articles with 5,265 citations and an h-index of 35.
In 2021, his team received the Innovative Small and Medium Enterprise Award for the project on mesial temporal lobe epilepsy and encephalocele (Ministry of Science and Innovation, Spain), and in 2012, the Scientific Award from the Epilepsy Group of the Spanish Society of Neurology (SEN).
Dr. Hill-Nagel is a leading international figure in the field of epileptology, a recognized expert in the diagnosis and treatment of genetic epilepsy and the surgical approach to its correction. His distinguished professional career includes many years of experience in leading medical institutions in the United States and Europe, as well as active participation in international research and educational programs.
Dr. Hill-Nagel not only advances the science of neurology on a global level, but also successfully implements cutting-edge treatment methods, improving the lives of thousands of patients around the world.
Dr Reema Arora has been a national and international trainer in BOTOX® and Fillers for the past 18 years. She has worked with Allergan India Pvt Ltd. as Medical Head- Facial Aesthetics and has the credit of training over 1500 Dermatologist and Plastic surgeons in the art of facial rejuvenation with injectables.
Dr. Arora has single handedly revolutionized the use of Botox and dermal fillers in India with new innovations and focus on Indian faces. She has perfected the art of using Botox, Juvederm, and Voluma amongst other injectables to rejuvenate, enhance and treat the whole face including -facial asymmetries, defining various facial features like the nose, jaw, lips and resolving excessive sweating.
Dr Reema Arora has been a national and international trainer in BOTOX® and Fillers for the past 18 years. She has worked with Allergan India Pvt Ltd. as Medical Head- Facial Aesthetics and has the credit of training over 1500 Dermatologist and Plastic surgeons in the art of facial rejuvenation with injectables.
Dr. Arora has single handedly revolutionized the use of Botox and dermal fillers in India with new innovations and focus on Indian faces. She has perfected the art of using Botox, Juvederm, and Voluma amongst other injectables to rejuvenate, enhance and treat the whole face including -facial asymmetries, defining various facial features like the nose, jaw, lips and resolving excessive sweating.
Dr. Arora made the switch to cosmetic medicine in 2006 following her passion for Aesthetics. She has been trained in Australia, Korea and Singapore with acclaimed dermatologist and plastic surgeons. Dr. Reema Arora is a medical graduate from St John’s Medical College Hospital and a postgraduate in Paediatrics.She went on to do her Masters in Aesthetic Medicine from London in 2018 and has gone on to become a brand in herself in Facial Aesthetics, continuously perfecting her well honed skills. Being India’s leading Rejuvenation expert for over 8 years, Dr. Reema Arora has always been a pioneer in Injectables. She constantly updates her techniques and extensive knowledge of the subject by attending training workshops and seminars.
Mostrar másDr Reema Arora has been a national and international trainer in BOTOX® and Fillers for the past 18 years. She has worked with Allergan India Pvt Ltd. as Medical Head- Facial Aesthetics and has the credit of training over 1500 Dermatologist and Plastic surgeons in the art of facial rejuvenation with injectables.
Dr. Arora has single handedly revolutionized the use of Botox and dermal fillers in India with new innovations and focus on Indian faces. She has perfected the art of using Botox, Juvederm, and Voluma amongst other injectables to rejuvenate, enhance and treat the whole face including -facial asymmetries, defining various facial features like the nose, jaw, lips and resolving excessive sweating.
Dr Reema Arora has been a national and international trainer in BOTOX® and Fillers for the past 18 years. She has worked with Allergan India Pvt Ltd. as Medical Head- Facial Aesthetics and has the credit of training over 1500 Dermatologist and Plastic surgeons in the art of facial rejuvenation with injectables.
Dr. Arora has single handedly revolutionized the use of Botox and dermal fillers in India with new innovations and focus on Indian faces. She has perfected the art of using Botox, Juvederm, and Voluma amongst other injectables to rejuvenate, enhance and treat the whole face including -facial asymmetries, defining various facial features like the nose, jaw, lips and resolving excessive sweating.
Dr. Arora made the switch to cosmetic medicine in 2006 following her passion for Aesthetics. She has been trained in Australia, Korea and Singapore with acclaimed dermatologist and plastic surgeons. Dr. Reema Arora is a medical graduate from St John’s Medical College Hospital and a postgraduate in Paediatrics.She went on to do her Masters in Aesthetic Medicine from London in 2018 and has gone on to become a brand in herself in Facial Aesthetics, continuously perfecting her well honed skills. Being India’s leading Rejuvenation expert for over 8 years, Dr. Reema Arora has always been a pioneer in Injectables. She constantly updates her techniques and extensive knowledge of the subject by attending training workshops and seminars.
Professor Dr. Gökmen
General Surgeon
Professor Dr. Gökmen
General Surgeon
Dr. Samir Göyüşov
Accessory Mental/Buccal Foramina: Case Report and Review of Literature
Goyushov S, Tözüm MD, Tözüm TF.
Journal: Implant Dentistry
Date: October 2017
Transplantation of Autogenous Bone Block with an Osseointegrated Implant: Seedling Technique
[Additional details can be included here if available]
The 2nd Baltic Osseointegration Academy and Lithuanian University of Health Sciences Consensus Conference 2019: Summary and Consensus Statements: Group 1-Biological Aspects of Tooth Extraction, Socket Healing and Indications for Socket Preservation
Gintaras Juodzbalys, Povilas Daugela, Onurcem Duruel, Maria Helena Fernandes, Pedro de Sousa Gomes, Samir Goyushov, Lorena Mariano, Lukas Poskevicius, Arturas Stumbras, Tolga Fikret Tözüm.
Journal: J Oral Maxillofac Res
Date: September 5, 2019
Morphological Classification of Extraction Sockets and Clinical Decision Tree for Socket Preservation/Augmentation after Tooth Extraction: a Systematic Review
Gintaras Juodzhalys, Arturas Stumbras, Samir Goyushov, Onurcem Duruel, Tolga Fikret Tanim.
Journal: J Oral Maxillofac Res
Date: September 5, 2019
Mandibular Cortical Indices and Their Relation to Gender and Age in Cone-Beam Computed Tomography
Samir Goyushov, Erhan Dursun, Tolga Fikret Tözüm.
Journal: Dentomaxillofac Radiol
Date: March 2020
An Alternative Treatment for Hopeless Implants: Coronal Resection
H Burak Kutlu, Samir Goyushov, Tolga F. Tözüm.
Journal: J Oral Biol Craniofac Res
Date: Apr-Jun 2020
Elevated Interleukin-17A Expression in Amlodipine-Induced Gingival Overgrowth
Siddika Selva Sume, Ezel Berker, Yagmur Ilarslan, Ozlem Ozer Yucel, Cagman Tan, Samir Goyushov, Sibel E Gultekin, Ilhan Tezcan.
Journal: J Periodontal Res
Date: October 2020
Three-Dimensional Calculation of Sinus Augmentation Volume after Maxillary Sinus Floor Elevation
Samir Goyushov, Erhan Dursun, Kaan Orhan, Tolga Tözüm.
Journal: Dent J
Date: May 2021
Dr. Samir Göyüşov
Accessory Mental/Buccal Foramina: Case Report and Review of Literature
Goyushov S, Tözüm MD, Tözüm TF.
Journal: Implant Dentistry
Date: October 2017
Transplantation of Autogenous Bone Block with an Osseointegrated Implant: Seedling Technique
[Additional details can be included here if available]
The 2nd Baltic Osseointegration Academy and Lithuanian University of Health Sciences Consensus Conference 2019: Summary and Consensus Statements: Group 1-Biological Aspects of Tooth Extraction, Socket Healing and Indications for Socket Preservation
Gintaras Juodzbalys, Povilas Daugela, Onurcem Duruel, Maria Helena Fernandes, Pedro de Sousa Gomes, Samir Goyushov, Lorena Mariano, Lukas Poskevicius, Arturas Stumbras, Tolga Fikret Tözüm.
Journal: J Oral Maxillofac Res
Date: September 5, 2019
Morphological Classification of Extraction Sockets and Clinical Decision Tree for Socket Preservation/Augmentation after Tooth Extraction: a Systematic Review
Gintaras Juodzhalys, Arturas Stumbras, Samir Goyushov, Onurcem Duruel, Tolga Fikret Tanim.
Journal: J Oral Maxillofac Res
Date: September 5, 2019
Mandibular Cortical Indices and Their Relation to Gender and Age in Cone-Beam Computed Tomography
Samir Goyushov, Erhan Dursun, Tolga Fikret Tözüm.
Journal: Dentomaxillofac Radiol
Date: March 2020
An Alternative Treatment for Hopeless Implants: Coronal Resection
H Burak Kutlu, Samir Goyushov, Tolga F. Tözüm.
Journal: J Oral Biol Craniofac Res
Date: Apr-Jun 2020
Elevated Interleukin-17A Expression in Amlodipine-Induced Gingival Overgrowth
Siddika Selva Sume, Ezel Berker, Yagmur Ilarslan, Ozlem Ozer Yucel, Cagman Tan, Samir Goyushov, Sibel E Gultekin, Ilhan Tezcan.
Journal: J Periodontal Res
Date: October 2020
Three-Dimensional Calculation of Sinus Augmentation Volume after Maxillary Sinus Floor Elevation
Samir Goyushov, Erhan Dursun, Kaan Orhan, Tolga Tözüm.
Journal: Dent J
Date: May 2021